(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 156.2MM | +0% |
Gross Profit | 65.5MM | -3% |
Cost Of Revenue | 90.8MM | +3% |
Operating Income | -30.6MM | +65% |
Operating Expenses | 96MM | +11% |
Net Income | -27.1MM | +89% |
R&D | 7.6MM | +7% |
G&A | 65.8MM | +10% |
Marketing | 20.2MM | +12% |
Amortization | 8.4MM | -5% |
Interest Expense | 1.7MM | -84% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript April 30, 2024 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.03. NEO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the NeoGenomics First Quarter 2024 Financial […]
NeoGenomics ( NASDAQ:NEO ) First Quarter 2024 Results Key Financial Results Revenue: US$156.2m (up 14% from 1Q 2023...
Discover how NeoGenomics is navigating market dynamics with robust revenue growth and strategic expansions in clinical diagnostics.
While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Insight into NeoGenomics' Financial Performance and Future Outlook
NeoGenomics (NEO) delivered earnings and revenue surprises of 33.33% and 4.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
FORT MYERS, Fla., April 30, 2024--NeoGenomics, Inc. announced its first-quarter results for the period ended March 31, 2024.
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FT. MYERS, Fla., April 18, 2024--NeoGenomics, Inc., announced two promotions within its senior leadership team, effective immediately.